Anwendungsgebiet
Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with:
- haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors.
- severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without FVIII inhibitors.
- haemophilia B (congenital factor IX deficiency) with FIX inhibitors.
- moderate/severe haemophilia B (congenital factor IX deficiency, FIX ≤ 2%) without FIX inhibitors.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.